Antibodies recognizing CCAR1 were present in 32% of patients with DM that were positive for anti–TIF1-γ in both cohorts and were found in only 1.5% of patients with scleroderma who possessed anti-POLR3A autoantibodies, suggesting good disease specificity. This evidence concerns the gene TRIM33 and dermatomyositis.